Navigation Links
Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/5/2008

HOPKINTON, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that Peter Savas, Chairman and CEO of Alseres Pharmaceuticals, Inc., will present Monday, November 10th at 2:00pm ET at Rodman & Renshaw Annual Healthcare Conference at the New York Palace Hotel in New York providing an overview on the Company and its therapeutic programs.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )

A live webcast will be available at:

http://www.wsw.com/webcast/rrshq14/alse

For more information on the conference and speaking companies please go to

http://www.rodm.com/conferences?id=19

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Alseres, Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.

Contact:

Sharon Correia - 508-497-2360 ext. 224

Alseres Pharmaceuticals, Inc.

scorreia@alseres.com

Adam Friedman - 212-981-2529 ext. 18

Adam Friedman Associates

adam@adam-friedman.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
2. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
3. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
4. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
5. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
6. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
7. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
8. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
9. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
10. Alseres Pharmaceuticals, Inc. Raises $5 Million
11. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... containerization, today announced an exhibitor sponsorship at MobileIron Live! 2017 in ... new technologies for an immersive, educational approach to helping organizations maximize the benefits ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, ... today announced it has completed a round of funding to accelerate its growth ... partners. Black Granite Capital is a growth equity firm focused on investments in ...
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... , ... RawTrition now brings you BioEnergy which is a powder capsule whole ... , RawTrition is taking nutrients to the next level! The superfoods in RawTrition's ... form (unlike the synthetically made options that are on the market). , Founder of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a leader ... in a new class of photodynamic cosmetics (PDC). , Allumera® is the first ... outward signs of aging, and minimize the appearance of pores – all with ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
Breaking Medicine Technology: